Corticosteroids are commonly prescribed to alleviate symptoms in lung cancer patients, but recent retrospective study results indicate that their use at the start of immune checkpoint inhibitor therapy may diminish treatment effectiveness. Patients with non-small cell lung cancer (NSCLC) who were on corticosteroids when initiating immunotherapy showed lower response rates, shorter progression-free survival (PFS), and overall survival (OS). The impact of steroids on immune function and survival outcomes was highlighted, emphasizing the need for a deeper understanding of how these medications influence immunotherapy responses.
The rationale behind corticosteroid use in NSCLC patients includes symptom relief and alleviation of treatment side effects such as vomiting, fatigue, lung inflammation, or brain swelling. Previous studies have suggested a negative association between corticosteroid use and immunotherapy outcomes, with factors like brain metastases, dyspnea, or patient characteristics potentially confounding the results. However, specific use of corticosteroids to manage immune-related adverse events did not seem to affect NSCLC patient outcomes under immunotherapy, indicating a nuanced relationship between steroid use and treatment response.
Research led by Dr. Jorge Nieva and colleagues evaluated the impact of baseline steroid use on immune checkpoint inhibitor therapy in NSCLC patients. The study included 277 patients across two institutions who received immunotherapy alone or in combination over an 8-year period. Notably, patients who were not on steroids at baseline had significantly higher response rates, longer PFS, and OS compared to those who were on corticosteroids. Furthermore, baseline neutrophil-to-lymphocyte ratio emerged as a predictive factor for PFS in nonsteroid users, underlining the importance of considering baseline characteristics in treatment strategies.
The association between steroid use and inferior outcomes in NSCLC patients receiving immunotherapy was consistent across cohorts from different institutions, strengthening the evidence of this relationship. The implications of these findings extend beyond NSCLC, potentially impacting the efficacy of immune checkpoint inhibitors in other cancer types like melanoma or kidney cancer. Understanding the mechanisms underlying the reduced efficacy of immunotherapy in steroid users, researchers identified a possible link between corticosteroids and the differentiation of effector T cells, suggesting a compromised immune response against cancer cells.
A subsequent preclinical study using mice confirmed that steroids negatively impacted the differentiation of T cells and the efficacy of anti-PD-1 therapy. However, discontinuing steroids at the start of treatment did not compromise survival outcomes, indicating a potential strategy to mitigate the negative effects of corticosteroids on immunotherapy. These findings underscore the need for further research to optimize the therapeutic potential of immunotherapy, with a focus on enhancing anti-tumor efficacy while minimizing factors that could impede treatment response.
In conclusion, the study underscores the critical role of shared decision-making in considering the benefits and limitations of corticosteroid use in cancer patients undergoing immunotherapy. Personalized treatment approaches that account for baseline steroid use and patient characteristics are essential to maximize treatment outcomes. Moving forward, identifying strategies to reduce the reliance on steroids in immunotherapy regimens may improve response rates and expand the benefits of immune checkpoint inhibitors to a broader patient population.
Tags: immunotherapy
Read more on healio.com